Europska Unija - engleski - EMA (European Medicines Agency)

teva b.v. - topotecan - ovarian neoplasms; uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - topotecan monotherapy is indicated for the treatment of: , patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy;, patients with relapsed small cell lung cancer [sclc] for whom re-treatment with the first-line regimen is not considered appropriate. , topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.,

Europska Unija - engleski - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. treatment of paget’s disease of the bone in adults.,

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 50/12.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 75/18.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 100/25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 125/31.25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 150/37.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 175/43.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Irska - engleski - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 200/50/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Europska Unija - engleski - EMA (European Medicines Agency)

teva b.v. - efavirenz - hiv infections - antivirals for systemic use - efavirenz is indicated in antiviral combination treatment of human-immunodeficiency-virus-1 (hiv-1)-infected adults, adolescents and children 3 years of age and older.efavirenz has not been adequately studied in patients with advanced hiv disease, namely in patients with cd4 counts < 50 cells/mm3, or after failure of protease inhibitor (pi)-containing regimens. although cross-resistance of efavirenz with protease inhibitors (pis) has not been documented, there are at present insufficient data on the efficacy of subsequent use of pi-based combination therapy after failure of regimens containing efavirenz.